Ivonescimab is a next-generation bispecific antibody that simultaneously targets programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF), two key molecules in the tumour microenvironment. This dual mechanism is thought to enhance therapeutic potential, as VEGF dimer leads to the potential interconnection or “daisy chaining” of multiple ivonescimab molecules, which may lead to increased binding of T cells. ​

However, details on these complexes – like their precise stoichiometry, affinities and complex formation dynamics between ivonescimab and its targets – have remained poorly characterized due to limitations of existing analytical techniques. ​

In this webinar, we will show how we used mass photometry, a single-molecule imaging technique capable of detecting biomolecular complexes in solution, to characterize ivonescimab’s binding behaviour with VEGF and PD-1. ​

We will show how real-time analysis enables the observation of complex formation throughout the incubation period as well as the quantification of the stability and prevalence of each complex. We will also show that we can calculate the dissociation constant for each complex in the equilibrium. Finally, we will demonstrate with real-world examples the importance of antigen QC for correctly interpreting complex dynamics.​

‘Join me to discover how mass photometry can advance design of the next generation of therapeutic bispecific antibodies, with rapid and quantitative insight into dynamic, complex, and multi-target antigen interactions.’​

Dr. Nina Jajcanin Jozic, Refeyn​